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Introduction
With 10.4 million new cases and 1.7 million deaths per year, 
tuberculosis (TB) remains a major global health problem1. 
Only 5%–15% of individuals infected with Mycobacterium 
tuberculosis (Mtb) ever develop TB disease, and over 50% of 
these do so within two years after infection2. Although risk 
factors for progression to TB disease have been identified3, 
disease occurrence cannot be accurately predicted4.
Recent data suggest that infection with human cytomegalovi-
rus (HCMV) is a predictor of TB disease in infants. In a cohort 
study of South African infants, an HCMV-specific IFN-γ T-cell 
response was associated with a 2.2-fold increased risk 
of TB disease over a period of up to 3 years. A similar response 
to Epstein-Barr virus (EBV) showed no such associations5. 
HCMV-positive and HCMV-negative infants had distinct 
immune pathways associated with TB disease. Although 
CD8+ T-cell activation was a distinguishing feature of HCMV- 
positive infants, the proposed immunological mechanism was 
impairment of the natural killer (NK) cell response. In African 
infants, HCMV infection induced profound CD8+ T-cell and 
NK cell differentiation and poor physical growth5–7.
The possibility that this association between HCMV and 
TB disease progression is causal, also holds in adults, and 
thus merits further study is dependent on its epidemiological 
plausibility. Only few published studies have investigated epi-
demiological associations between the two diseases8–10. Despite 
this paucity of direct evidence we argue that the epidemiol-
ogy of TB and HCMV share important similarities that make 
HCMV infection a plausible candidate as a cause of TB disease 
progression.
Viral triggers of tuberculosis disease
Various etiological frameworks for TB disease progression 
have been developed. One proposed by Comstock considers 
TB disease the result of two hits or causes, one of which is Mtb 
infection, and the other (still) unknown11. In this framework, 
factors that strongly increase the risk of TB disease such as 
HIV infection or anti-tumour necrosis alpha therapy may act as 
a second hit but would not account for all or most TB cases.
Several factors have been identified that increase the risk of 
disease progression, such as low body-mass index12, diabetes13, 
tobacco smoking14, and alcohol abuse15. As their effects are mod-
est another framework has emerged that these are predisposing 
conditions for disease progression while other, yet unidentified 
precipitating events are needed to trigger progression to active 
disease16. Among the precipitating events suggested are viral 
infections, possibly through induction of Type I interferons (IFN). 
Elevated Type I IFN signalling is a hallmark of viral control, however, 
Type I IFN is also associated with susceptibility to bacterial infec-
tions, including Mtb17–22. The Type I IFN response is tightly regulated 
by prostaglandins and the balance between prostoglandins PGE2 
and LXA4 can be manipulated by Mtb to drive Type I IFN mediated 
necrosis and promote mybobacterial dissemination19,23. Type I IFN- 
associated impairment of the immunity against Mtb has been 
shown for influenza A21. A role for influenza A infection has also 
been suggested by epidemiological data. Notification of TB tends 
to peak in the months after winter when most respiratory viruses 
circulate24, and TB mortality has shown increases during influenza 
epidemics25,26. However, careful analysis of seasonality data sug-
gests that it is TB transmission rather than disease progression that 
is increased in winter27, and increased TB mortality during influenza 
epidemics may reflect increased case fatality among TB patients 
due to secondary influenza rather than increased TB incidence. 
As with many viral infections, Type I IFN can control HCMV 
replication28,29. HCMV has been suggested in three studies from 
Nigeria, Russia and Uganda that all found higher prevalence or 
levels of IgG HCMV antibodies in diagnosed TB patients 
compared to healthy controls and patients diagnosed with other 
diseases8–10.
Human cytomegalovirus infection
HCMV, human herpesvirus 5, is a double-stranded DNA 
virus. After primary infection, usually through mucosal con-
tact, HCMV remains dormant in the host’s myeloid tissues but 
can reactivate if immunity is compromised. Primary infection 
is often asymptomatic but can present as mononucleosis with 
fever, pharyngo-tonsillitis and lymphadenopathy. In congenitally 
infected infants HCMV may cause severe generalized infec-
tion with high case fatality and neurologic sequelae30. Gener-
alized infection also occurs in severely immunocompromised 
adults, usually through reactivation. During primary infection 
and reactivation virus is shed in the urine, saliva, breast milk, 
cervical fluid and semen31. Common routes of transmission 
are from mother to child during delivery, between children 
and by sexual contact. Transmission through blood transfusion 
and solid organ transplantations also occurs. 
HCMV viruses show genomic diversity, in particular in genes 
coding for envelope glycoproteins, and polymorphisms in these 
genes have been used to genotype strains32,33. Both immunocom-
promised and immunocompetent individuals can be re-infected 
and harbour multiple HCMV strains34–36.
Primary HCMV infection is characterized by profound 
expansion of antigen specific CD8+ and CD4+ T cells and 
NK cell populations with specificity for HCMV37. HCMV 
expanded NK cells can display inappropriate homing to tissue 
infected with other pathogens and lower IFN-γ secretion in 
response to pathogens38. HCMV infection drives the expansion of 
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CD94/NKG2C NK cells and these cells are important for control of 
viral replication39. In HCMV positive infants who progressed to 
TB disease in the South African cohort there was lower expres-
sion of CD94 and NKG2C (KLRD1 and KLRC3) transcripts and 
lower frequency of NK cells5. The NKG2C receptor is encoded 
by the KLRC2 gene which is deleted in approximately 10% of 
individuals40. The KLRC2 gene deletion is associated with lower 
numbers of mature NK cells and increased risk of HIV infec-
tion and disease progression41,42, as well as with susceptibility to 
autoimmune conditions and cancer40. Susceptibility to TB in this 
infant population may be due to loss of control of CMV infection 
due to KLRC2 gene defects in some individuals.
HCMV has multiple immune evasion strategies37, which may 
make the microenvironment around latently infected mye-
loid cells suppressive to T-cell function, potentially creating 
an environment permissive for mycobacterial growth43,44. This may 
be through effects of HCMV on the systemic immune response, 
but also through local effects. The lung is a reservoir of HCMV 
infection45,46 and frequently the site of viral reactivation47, which 
drives inflammation and in mice may cause pulmonary fibrosis48. It 
is therefore possible that active HCMV (re)infection or  reactivation 
of latent HCMV could precipitate progression to TB disease.
Epidemiological convergence
Both Mtb and HCMV infections are ubiquitous1,49, and dur-
ing millions of years of co-evolution have become highly human 
host-specific50–52. An animal reservoir has been described for 
neither Mtb nor HCMV (several monkey and rodent species 
have their distinct CMV species), implying that their 
epidemiological patterns are entirely determined by transmission 
between, and carriage by, humans. 
We hypothesize that immunologically active HCMV infection, 
whether primary, reactivation or re-infection, acts as (depend-
ing on one’s preferred framework) second-hit or precipitating 
factor for progression of latent TB infection to TB disease at 
an epidemiologically relevant scale. We base this on two 
arguments: their striking similarity in age distribution, and the 
existence of congruent risk factors [Box 1].
Box 1. Approach to evidence gathering
We systematically searched PubMed for the following 
combinations of keywords: tuberculosis and cytomegalovirus; 
cytomegalovirus and prevalence or seroprevalence; 
cytomegalovirus and age; cytomegalovirus and reinfection; 
cytomegalovirus and sexual; tuberculosis and sexual; 
tuberculosis and sexual transmitted infections or Chlamydia 
or gonorrhoea or human papillomavirus; tuberculosis and 
blood transfusion; cytomegalovirus and blood transfusion; 
tuberculosis and gastrectomy; cytomegalovirus and renal 
dialysis; tuberculosis and renal dialysis; tuberculosis and organ 
transplantation; cytomegalovirus and organ transplantation.
We in addition made use of an extensive review of the literature 
on age-sex distribution of tuberculosis incidence published by 
Nagelkerke (2012)53.
Age distribution
The probability of progressing from TB infection to disease has 
a highly typical age distribution. The classical description of this 
age pattern is by Comstock et al, who followed 82,269 Puerto 
Rican children reacting to tuberculin enrolled in 1949–1951 
for 8 to 20 years [Figure 1]54. This pattern, confirmed in a 
systematic review of studies from the pre-chemotherapy era55, 
is defined by a peak in the first 1–4 years of life, followed by a 
trough until early puberty, rising to a second peak around the 
age of 20 years. Analyses of notification and prevalence data from 
high-incidence countries show that incidence starts to rise again 
from the sixth decade56,57. Although several explanations for this 
age pattern have been suggested, none has been proven.
Infants. Studies from the pre-chemotherapy era showed that, 
while the risk of infection with Mtb in the first year of life 
was over 10-fold lower than later in childhood, the risk of 
progression to disease once infected was much higher with up 
to 50% of infected infants developing disease55. These high 
progression rates have been attributed to age-specific maturation 
of immune responses58, although the mechanisms responsible 
for this vulnerability have not been elucidated59.
HCMV infection in infants is common60. Depending on the 
country and socio-economic status of the mother, between 10 and 
60% of children are HCMV IgG seropositive (reflecting current 
or past active infection) by the age of 12–36 months61–68. Impor-
tant causes are congenital infection and transmission through 
breastfeeding; >85% of HCMV seropositive women excrete 
virus in the breastmilk60,69–72. Infants infected through breast-
feeding do not develop disease, probably due to protection by 
maternal antibodies, but do shed virus in saliva and urine 
intermittently for months, by which they may transmit HCMV 
to other children and caregivers31,60,64,73. Shedding of HCMV 
shows a steep decline by the age of 5 years31, coinciding with the 
age at which TB incidences drop54,55.
Figure 1. Age-specific incidence of tuberculosis disease among 
tuberculin-reactive children. Average annual rate of tuberculosis 
disease in a cohort of 82,269 Puerto Rican children with a positive 
tuberculin skin test, by age of disease occurrence. Children were 
enrolled in the period 1949–1951, and followed for 8 to 20 years. 
Figure reproduced with permission from Comstock et al. (1974)54.
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Adolescents. The rate of progression to TB disease then remains 
low until puberty. Several studies have observed an increase 
in TB incidence from this age onward among children who 
were exposed to infectious TB patients or had a positive 
tuberculin response, leading to a peak in incidence in the first 
half of the third decade54,74–79. This phenomenon has been 
attributed to hormonal changes, but again without a putative 
mechanistic pathway80.
Most population-based studies of HCMV seroprevalence 
show exactly this age pattern: a slow increase in HCMV IgG 
seroprevalence up to the age of 10–15 years, followed by an 
acceleration during adolescence61,63–66,68,81–88. One explanation 
for this increase in seroprevalence is sexual transmission. Vari-
ous studies found that HCMV conversion among women was 
associated with sexual activity89–93. However, as several stud-
ies of adolescents found no association of HCMV seropreva-
lence with sexual exposure83,94,95, other transmission routes 
such as mouth-to-mouth kissing may also be important.
Another indication that HCMV infection may be implicated 
is the sex difference in TB disease progression in the second 
decade. For girls the increase in TB incidence starts 2–4 years 
earlier than for boys, and progression rates tend to remain 
higher in women than in men for the subsequent two decades, 
a pattern that was observed before the HIV era in various 
populations54,75,76,78,79,96–99. This pattern is again reflected in 
that of HCMV infection. The acceleration of HCMV 
seroprevalence during puberty and adolescence is steeper in 
girls than in boys and is higher in women of childbearing age 
than in men in populations with relatively low HCMV 
seroprevalence49,64,65,84,100–102. Age-adjusted HCMV seroprevalence 
does not differ between men and women in populations 
with high seroprevalence49,103. This may be because IgG 
seroprevalence measures cumulative infection experience and 
thus ignores reinfection. HCMV reinfection, identified by 
DNA typing or strain-specific antibody responses, is a common 
occurrence in sexually exposed women104–106.
Elderly. Although there is little data on TB progression rates in 
the elderly, age patterns of TB notifications suggest increased 
progression rates from the sixth decade onward1,56. In popula-
tions with declining incidence rates over the past decades this 
is partially a cohort effect, whereby younger generations have 
lower prevalence of latent infection107,108. However in 
high-incidence countries with little change in TB incidence, 
notification rates clearly increase at older age1. This is also 
observed for TB prevalence in population surveys, suggesting 
that this is not explained by better access to diagnosis1. 
HCMV infection has been implicated as a cause of age-related 
decrease in naïve T cells and increase in memory T cells known 
as immunosenescence109. However, reactivation of HCMV 
infection is also common at old age, probably reflecting 
weakening immune control37. Detection of viral DNA increases 
after the age of 60–70 years110,111, and viral DNA is frequently 
detected in urine and plasma of elderly people112,113.
Congruent risk factors
Our hypothesis predicts that factors that drive CMV (re-)infection 
are also risk factors for TB. We highlight the four most 
important: socio-economic status, sexual contact, blood 
transfusion, and solid organ transplantation.
Socio-economic status. Incidence and prevalence of CMV 
infection are associated with poor socio-economic sta-
tus (SES), between countries as well as within countries and 
communities49,64,65,100,114–116. This includes association with crowd-
ing, in particular the number of young children in household117–119. 
Several studies found ethnicity or migrant status to be inde-
pendently associated with age-adjusted CMV prevalence65,84,120, 
which may partly reflect higher background infection rates 
in the country of origin. In a US study the association 
with ethnicity was explained by differences in exposure 
to infants and sexual risk93.
Also the incidence of TB, often regarded as the archetypal pov-
erty disease, shows a remarkable inverse gradient with SES at 
the household, regional and country level121–123. This association 
has been explained mainly by crowding in ill-ventilated spaces 
conducive to Mtb transmission124, poor nutritional status12,125, 
alcohol abuse15 and, possibly, indoor air pollution126. Simi-
larly, in low-incidence countries, TB incidences are higher in 
particular ethnic groups and immigrants127,128, which also may 
reflect socio-economic disparities and differences in background 
infection rates129. Very few studies have attempted to investigate 
whether these and other known risk factors explain all of the 
observed variation in SES-related TB incidence130.
Sexual contact. The risk of CMV (re-)infection in adults is cor-
related with measures of sexual activity such as age at first 
intercourse, recent and lifetime number of sexual partners and 
condom use, as well as with prevalence of other sexually trans-
mitted infections89,90,92,131–133. Historically, TB has also been 
associated with sexual promiscuity in medical and popular 
literature (reviewed in 53) but no systematic epidemiologi-
cal data exist. Investigation of associations between TB disease 
and sexually transmitted infections has been strongly 
dominated by HIV infection, which may obviously be a 
major confounder. There have been few studies from low 
HIV prevalence populations. One from China found an 
association between history of TB and human papilloma virus 
infection134.
Interestingly, the declining TB mortality rates in The Netherlands 
and England and Wales in the 20th century showed no surge 
during the Great Depression121,135, when SES status deterio-
rated thereby affecting several of these known risk factors, in 
particular nutritional status. They did however surge during 
and shortly after the Second World War121,135. In England and 
Wales this was not paralleled by major deterioration 
in nutritional status; in The Netherlands famine only started 
in the winter of 1944–45 while the increase in TB mortality 
started already from 194253. In both countries during this 
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period major increases were seen in sexually transmitted 
infections, mainly related to presence of large numbers of 
Allied and Axis troops53.
Blood transfusion. Transfusion-associated CMV infection 
occurs in particular following multiple transfusions of whole 
blood or granulocytes, and can be prevented by removal of 
white blood cells136–138. Increased incidences of TB have indeed 
been described in two categories of patients who in the past 
often received multiple whole blood transfusions: patients 
who underwent (partial) gastrectomy, mainly for bleeding 
gastric ulcers139,140, and patients with end-stage renal dis-
ease on haemodialysis141. For both these categories alterna-
tive explanations for increased TB incidences are possible: low 
body mass index for gastrectomy139,140, and impaired cellular 
immunity due to uraemia for haemodialysis142. Nonetheless, 
several studies among haemodialysis patients have suggested 
increased rates of CMV (re)infection, either or not associated 
with transfusion of blood or blood products143–147, as well as 
increased rates of CMV reactivation143.
Solid organ transplantation. The incidence of symptomatic 
CMV infection is strongly increased in solid organ transplant 
patients, mainly due to infection from a CMV IgG positive 
donor148. Solid organ transplantation also increases the risk of TB 
disease141,149–151. TB incidence is highest in lung transplant patients 
and associated with presence of latent TB infection, clinical con-
dition and intensity of the immunosuppressive therapy; the latter 
has been brought forward as the sole explanation for the increased 
TB risk152. Interestingly, a study among Korean solid organ 
transplant patients found that the risk of developing TB was 
associated with CMV infection within the prior 3 months153.
Potential impact on tuberculosis control and 
elimination
If indeed CMV (re-)infection or reactivation commonly 
precipitates progression from latent infection to active TB, this 
will suggest novel approaches to TB control. Combining a test 
for Mtb infection with one for ongoing or recent active CMV 
infection may strongly increase our ability to predict the devel-
opment of TB disease and allow the targeting of preventive 
treatment to those most at risk4. Vaccination against CMV might 
prevent TB in those with TB infection. A wide range of CMV 
vaccines  are currently in clinical development including 
plasmid-based vaccines, viral vector vaccines, attenuated HCMV 
strains, and recombinant protein and peptide vaccines154. Recently, a 
genetically modified CMV vector expressing antigens from Mtb 
(RhCMV/TB) has shown some protection against Mtb in a non-
human primate study155. If the human version of this vaccine was 
able to afford (partial) protection against CMV, it could also sig-
nificantly impact the TB epidemic. However, there is currently 
no widely available HCMV vaccine and it is unclear if vaccines 
based on HCMV in humans will offer similar protection to those 
based on RhCMV in non-human primates. Since CMV infection 
may also affect TB treatment response, another potential 
application therefore could be the provision of CMV antiviral 
treatment as an adjunct to TB treatment, for example of patients 
with multidrug resistance. 
Future research
There is an urgent need for elucidating the role of CMV infec-
tion in TB disease progression. Further serological and cellular 
studies should be done to confirm the association between TB 
disease and CMV infection. However, in settings with high CMV 
seroprevalence (also those with highest TB incidence) it will be 
important to identify recent reinfection for which various diagnos-
tic approaches exist30. Their relative merits are beyond the scope 
of this article, but some may potentially signal reactivation due 
to Mtb replication, i.e. consequence rather than cause. Therefore, 
ultimately longitudinal studies are needed in which the incidence 
of TB disease among those with latent TB infection is measured 
over time comparing those with CMV (re-)infection or reactiva-
tion to those without. These studies should be supplemented with 
immunological studies to define the mechanisms through which 
CMV precipitates progression to active TB disease. Finally, 
it will be important to study the role of CMV reactivation during 
TB disease and its effect on the response to TB treatment.
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